Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome-Reference-Cited by-同舟云学术

Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome

Published:2019-07-04 Issue:3 Volume:187 Page:337-346
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Berger Marc G.¹²³^ORCID,Pereira Bruno⁴,Rousselot Philippe⁵,Cony‐Makhoul Pascale⁶^ORCID,Gardembas Martine⁷,Legros Laurence⁸,Escoffre‐Barbe Martine⁹,Nicolini Franck‐Emmanuel¹⁰,Saugues Sandrine¹,Lambert Céline⁴,Réa Delphine¹¹^ORCID,Guerci‐Bresler Agnès¹²,Giraudier Stéphane¹³,Guilhot Joëlle¹⁴,Saussele Susanne¹⁵,Mahon François‐Xavier¹⁶,

Affiliation:

1. CHU Clermont‐Ferrand, Hôpital Estaing, Hématologie Biologique Clermont‐Ferrand Cedex France

2. Service d’Hématologie Clinique Adulte et Thérapie Cellulaire CHU Clermont‐Ferrand, Hôpital Estaing Clermont‐Ferrand Cedex France

3. Université Clermont Auvergne, EA 7453 CHELTER Clermont‐Ferrand Cedex France

4. Délégation de la Recherche Clinique et de l’Innovation CHU Clermont‐Ferrand Clermont‐Ferrand France

5. Service d’Hématologie et d’Oncologie CH de Versailles Le Chesnay France

6. Service Hématologie Clinique Centre Hospitalier Annecy Genevois Pringy France

7. Service des Maladies du Sang CHU Angers Angers France

8. Service d’Hématologie Clinique Hôpital Paul‐Brousse (AP‐HP) Villejuif France

9. Service d’Hématologie Clinique CHU Rennes Rennes France

10. Hématologie Clinique et INSERM U1052 Centre Léon Bérard Lyon France

11. Groupe Hospitalier Saint‐Louis Service d’Hématologie Lariboisière, Fernand‐Widal (AP‐HP) Paris France

12. Service d’Hématologie Clinique CHRU Nancy‐Brabois Vandoeuvre France

13. Laboratoire d’Hématologie Hôpital H. Mondor Créteil France

14. INSERM CIC CHU Poitiers Poitiers France

15. III Medizinische Klinik, Medizinische Fakultät Mannheim Universität Heidelberg Mannheim Germany

16. Bergonié Institute Cancer Center Bordeaux France

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16083

Reference36 articles.

1. Imatinib Mesylate: An Innovation in Treatment of Autoimmune Diseases

2. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

3. Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors

4. Nilotinib inhibits the Src-family kinase LCK and T-cell function in vitro

5. Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse.;Annals of Oncology;2024-09

3. Chronic myeloid leukaemia: Biology and therapy;Blood Reviews;2024-05

4. High Level of CD8+PD-1+ Cells in Patients with Chronic Myeloid Leukemia Who Experienced Loss of MMR after Imatinib Discontinuation;Cells;2024-04-22

5. Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF;Leukemia;2024-03-12